Industries in Depth

Why we might be overlooking important scientific breakthroughs

This article is published in collaboration with NBER Digest.
Molecular Genetics Technical Specialist Jaime Wendt (R) and Mike Tschannen work in the Human and Molecular Genetics Center Sequencing Core at the Medical College of Wisconsin in Milwaukee May 9, 2014. Once strictly the domain of research labs, gene-sequencing tests increasingly are being used to help understand the genetic causes of rare disease, putting insurance companies in the position of deciding whether to pay the $5,000 to $17,000 for the tests. Genetics experts say that sequencing more than doubles the chances that families get a diagnosis, and saves spending on multiple tests of single genes. Even if no treatment is found, the tests can also end hugely expensive medical odysseys as parents frantically search for the cause of their child's furtive illness. Picture taken May 9, 2014. To match Insight HEALTH-SEQUENCING/ REUTERS/Jim Young (UNITED STATES - Tags: SCIENCE TECHNOLOGY HEALTH SOCIETY BUSINESS) - RTR3UNAX

Gene sequencing at The Medical College of Wisconsin. Image: REUTERS/Jim Young

Matt Nesvisky
Share:
Our Impact
What's the World Economic Forum doing to accelerate action on Industries in Depth?
The Big Picture
Explore and monitor how Justice and Law is affecting economies, industries and global issues
A hand holding a looking glass by a lake
Crowdsource Innovation
Get involved with our crowdsourced digital platform to deliver impact at scale
Stay up to date:

Justice and Law

Research based on an unusual or novel approach may lead to important breakthroughs in science, but peer evaluators are often overly cautious in evaluating such work, Jian Wang, Reinhilde Veugelers, and Paula Stephan find in Bias against Novelty in Science: A Cautionary Tale for Users of Bibliometric Indicators (NBER Working Paper No. 22180). They argue that this excess caution represents a flaw in the traditional means of evaluating research, and that this flaw has far-reaching implications for the allocation of resources.

Novelty and Citations- highly novel papers have less impact early, more later
Image: NBER

The researchers define novel research as being based on "the recombination of pre-existing knowledge components in an unprecedented fashion." An outstanding example of such work occurred in the 1950s when Leo Szilard applied his expertise as a nuclear physicist to the field of biology and the cloning of cells. The study finds that novel papers, which represent 11 percent of all papers, are often cited infrequently in research journals for a significant period of time. Because frequency of citation is the standard for evaluating scientific papers, this finding suggests that evaluation of research based on short time windows is biased against novel research.

The study analyzes citation patterns involving Web of Science papers that were indexed in 2001—some 773,311 research articles across all disciplines. It identifies papers that use new combinations of knowledge pieces, then tracks how soon, how often, and in which fields such research is cited by other publications. The researchers find that novel studies are less likely to be published in high-impact-factor journals, but eventually have a much higher chance of being in the top one percent of highly cited research, and that they are more likely to lead to important follow-up research. But it takes time for this impact to develop.

The researchers argue that classic bibliometric evaluations that focus on citation counts over a relatively short post-publication period and in the most prominent journals can lead to bias against novel research. They suggest that citation-based bias can cause funding agencies to favor "safer" projects over novel ones. Using short time windows for measuring citations and the impact factor of the publishing journal makes it more difficult to marshal support for novel research projects, even though this research is often among the most fruitful of scientific inquiries.

The researchers suggest the use of a wide portfolio of indicators and of time windows beyond the standard two or three years, when bibliometric indicators are used as part of evaluation processes.

They also find that the major impact of novel research comes largely from disciplines beyond its own field. Therefore restricting peer review to scientists solely within the discipline, they conclude, "may fail to recognize the full value of novel research."

Don't miss any update on this topic

Create a free account and access your personalized content collection with our latest publications and analyses.

Sign up for free

License and Republishing

World Economic Forum articles may be republished in accordance with the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Public License, and in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

Share:
World Economic Forum logo
Global Agenda

The Agenda Weekly

A weekly update of the most important issues driving the global agenda

Subscribe today

You can unsubscribe at any time using the link in our emails. For more details, review our privacy policy.

Confused about AI? Here are the podcasts you need on artificial intelligence

Robin Pomeroy

April 25, 2024

About Us

Events

Media

Partners & Members

  • Join Us

Language Editions

Privacy Policy & Terms of Service

© 2024 World Economic Forum